Adaptive and Amgen collaborate to develop therapeutic antibodies against SARS-CoV-2
Adaptive has partnered with Amgen to discover and develop fully human neutralizing antibodies, aiming to help solve the current global pandemic crisis by combining expertise to discover and develop a fully-human neutralizing antibody targeting SARS-CoV-2 to potentially speed the recovery from or prevent COVID-19.
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and provide passive immunity to people who have recently been exposed to SARS-CoV-2.
Adaptive will extend its high-throughput immune medicine platform to rapidly screen the massive genetic diversity of the B-cell repertoire. This enables us to identify tens of thousands of naturally occurring BCRs from survivors of COVID-19 to characterize the best antibodies that neutralize SARS-CoV-2 and potentially other related coronaviruses. Then Amgen will apply its world class antibody engineering capabilities to develop, manufacture, and commercialize neutralizing antibodies for COVID-19.